27912-14-7CC(C)(C)NCC(O)COc1cccc2c1CCCC2=O.ClDNTDOBSIBZKFCP-UHFFFAOYSA-NSee also: Levobunolol (related).
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
説明Levobunolol hydrochloride is a non-selective β-adrenergic blocker useful in the treatment of glaucoma. Worldwide, it represents the sixth B-blocker to be launched for this indication.
使用Anti-adrenergic (β-receptor).
現在のフィルター条件では反応記録がありません。
読み込み中…
27912-14-7、31969-05-8DTXSID50953855CHEMBL2106021定義ChEBI: A hydrochloride obtained by combining equimolar amounts of levobunolol and hydrochloric acid. A non-selective beta-adrenergic antagonist used for treatment of glaucoma.